4BSB.F · 4basebio AG

-

Please sign in to comment on 4BSB.F

1 Comment

Admin

3 years, 7 months ago

4basebio AG is currently in a long term downtrend where the price is trading 6.0% below its 200 day moving average.

From a valuation standpoint, the stock is 94.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 77.4.

4basebio AG's total revenue sank by 93.0% to $289K since the same quarter in the previous year.

Its net income has dropped by 518.5% to $-1M since the same quarter in the previous year.

Finally, its free cash flow fell by 652.0% to $-925K since the same quarter in the previous year.

Based on the above factors, 4basebio AG gets an overall score of 1/5.

ISIN	None
Sector	Healthcare
Industry	Drug Manufacturers-Specialty & Generic
CurrencyCode	EUR
Exchange	F

Target Price	None
Beta	0.74
PE Ratio	1.54
Market Cap	93M
Dividend Yield	None

ABOUT

4basebio AG

4basebio AG, an enabler of advances in medical science and patient care, focuses on manufacturing DNA products for therapeutic and other uses in Europe, the United States, and internationally. It also focuses on providing research and diagnostic products based on its RNA reverse transcriptase, DNA polymerase, and DNA primase enzymes, addressing the research tools and diagnostic products markets. The company was formerly known as Expedeon AG and changed its name to 4basebio AG in January 2020. 4basebio AG is based in Heidelberg, Germany.

4BSB.F · 4basebio AG

-

4basebio AG

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest 4basebio AG using a moving average strategy